SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZTC -- Ignore unavailable to you. Want to Upgrade?

To: kinkblot who wrote (613)9/16/1999 5:31:00 PM
From: H. Bradley Toland, Jr.  Read Replies (1) | Respond to of 752
 
Hi Will,

We're long term holders of GZTC and your two last posts are really big news for GZTC. It's our understanding that they are in the process of developing goats now to produce Remicade (have already expressed it successfully in mice).

regards,

bt



To: kinkblot who wrote (613)9/17/1999 10:01:00 AM
From: kinkblot  Read Replies (1) | Respond to of 752
 
Researchers find new tumor-starving compound

abcnews.go.com

"Antithrombin normally binds excess thrombin so you don't get (blood) clots in your legs. But inside there is this slightly smaller compound [aaAT] that does something else."
-- Dr. Judah Folkman

Wire story has a few more details and some comments from Folkman.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News